- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07471139
SWITCH: Apixaban mot K-vitamin i HM3
SWITCH-studien: En randomiserad kontrollerad studie av apixaban jämfört med K-vitaminantagonister hos patienter med HeartMate 3 vänsterkammarassistansdon
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Heart failure is a global epidemic, and Left Ventricular Assist Devices (LVADs) - particularly the HeartMate 3 (HM3) - are increasingly used due to their survival benefit over medical therapy. Despite advances, hemocompatibility-related adverse events (HRAEs) like thrombosis and bleeding remain significant causes of morbidity and mortality.
Direct Oral Anticoagulants (DOACs) have shown superiority over warfarin in heart failure patients, with lower rates of embolic and intracranial bleeding. Reduced-dose DOACs also appear to reduce major bleeding without increasing thrombotic risk. However, data on their use in LVAD patients is limited, consisting mainly of case reports, small series, retrospective analyses, and a few small randomized clinical trials.
Some reports suggest apixaban may reduce bleeding in high-risk LVAD patients, though cases of pump thrombosis and stroke have occurred. Early studies comparing DOACs to warfarin in patients with HeartMate II (HMII), HeartWare™ HVAD™ System, and The Abbott HeartMate 3 (HM3) show no significant differences in outcomes, with a trend toward less bleeding with apixaban. Two small randomized clinical trials in HM3 patients (The DOAC LVAD Study and The DOT-HM3 Study) found similar results.
This prospective, randomized, controlled, non-inferiority trial will evaluate the safety and efficacy of apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Ilan Richter, MD
- Telefonnummer: 3322098345
- E-post: ir2498@cumc.columbia.edu
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Rekrytering
- Columbia University Irving Medical Center
-
Kontakt:
- Ilan Richter, MD
- Telefonnummer: 212-305-7600
- E-post: ir2498@cumc.columbia.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Participants will have HeartMate3 LVAD implanted > 3 months before enrollment
- ≥ 18 years old
- Treated with WARFARIN SODIUM
- Participant must provide written informed consent prior to any clinical investigation related procedure
- In female participants of childbearing capability, not currently pregnant and on appropriate contraception
Exclusion Criteria:
- Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- Known allergy to Apixaban
- Bridge to transplant
- Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) <20
- History of major bleeding event with subsequent reduction of INR goal to < 1.8
- Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Aortic root thrombus
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Warfarin
Participants will take warfarin, dose titrated for an INR >= 1.8 |
Warfarin dose titrated for an International Normalized Ratio (INR) >= 1.8
Andra namn:
|
|
Experimentell: Apixaban
Participants wil take apixaban 5 mg bid |
Apixaban 5 mg bid (twice a day)
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Survival free of major hemocompatibility related adverse event
Tidsram: 12 months
|
Major Hemocompatibility Related Adverse Event: Stroke, Pump Thrombosis, major non surgical Bleeding (moderate or severe), Arterial Peripheral Thromboembolism. Rates will be compared between study groups. |
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Non-surgical Major Hemorrhagic Events
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Non-surgical Major Thrombotic Events
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Survival
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Stroke Rates
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Pump Thrombosis Rates
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Bleeding Rates
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
|
Rates of listing for Heart Transplant
Tidsram: 12 months
|
Rates will be compared between study groups. |
12 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Apixabannivåer hos patienter som drabbats av biverkning
Tidsram: 12 månader
|
12 månader
|
|
|
Patient functional status
Tidsram: 12 months
|
Association between anticoagulant regimen and New York Heart Association (NYHA) Functional Classification (FC) will be compared between groups. Scores range I through IV, with higher scores indicating worse outcome. |
12 months
|
|
Patient QOL
Tidsram: 12 months
|
Kansas City Cardiomyopathy Questionnaire (KCCQ) 12 scores will be compared between groups. Scores range 1-100, with higher scores indicating better health status. |
12 months
|
|
LVAD device speed
Tidsram: 12 months
|
LVAD speed (mean, SD) of LVAD will be compared between study groups. Speed ranges 4500-6000 RPM. |
12 months
|
|
LVAD device flow
Tidsram: 12 months
|
LVAD flow (mean, SD) of LVAD will be compared between study groups. Flow ranges 3-6 L/min. |
12 months
|
|
LVAD device pulsatility index
Tidsram: 12 months
|
LVAD pulsatility index (PI) will be compared between study groups. PI ranges 1-4 (no units). |
12 months
|
|
LVAD device power
Tidsram: 12 months
|
LVAD power (mean, SD) will be compared between study groups. Power ranges 3-7 W. |
12 months
|
|
Right atrial pressure
Tidsram: 12 months
|
Right atrial (RA) pressure (mean, SD) will be compared between study groups. RA ranges 0-20 mmHg. |
12 months
|
|
Right ventricular systolic pressure
Tidsram: 12 months
|
Right ventricular (RV) systolic pressure (mean, SD) will be compared between study groups. RV systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Right ventricular diastolic pressure
Tidsram: 12 months
|
Right ventricular (RV) diastolic pressure (mean, SD) will be compared between study groups. RV diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery systolic pressure
Tidsram: 12 months
|
Pulmonary artery (PA) systolic pressure (mean, SD) will be compared between study groups. PA systolic pressure ranges 0-100 mmHg. |
12 months
|
|
Pulmonary artery diastolic pressure
Tidsram: 12 months
|
Pulmonary artery (PA) diastolic pressure (mean, SD) will be compared between study groups. PA diastolic pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary artery mean pressure
Tidsram: 12 months
|
Pulmonary artery (PA) mean pressure (mean, SD) will be compared between study groups. PA mean pressure ranges 0-50 mmHg. |
12 months
|
|
Pulmonary capillary wedge pressure
Tidsram: 12 months
|
Pulmonary capillary wedge pressure (PCWP, mean, SD) will be compared between study groups. PCWP ranges 0-50 mmHg. |
12 months
|
|
Cardiac output
Tidsram: 12 months
|
Cardiac output (CO, mean, SD) will be compared between study groups. CO ranges 3-10 L/min. |
12 months
|
|
Invasive hemodynamics
Tidsram: 12 months
|
Cardiac index (CI, mean, SD) will be compared between study groups. CI ranges 2.5-4 L/min/m^2. |
12 months
|
|
Drive line infection rates
Tidsram: 12 months
|
Rate of drive line infections will be compared between study groups. |
12 months
|
|
VAD coordinator time
Tidsram: 12 months
|
Means will be compared between study groups. |
12 months
|
|
Laboratory monitoring
Tidsram: 12 months
|
A quantitative comparison of performed laboratory tests to monitor anticoagulation between groups (counts) |
12 months
|
|
Days hospitalized
Tidsram: 12 months
|
Means will be compared between study groups. |
12 months
|
|
Caregiver burden
Tidsram: 12 months
|
Self assessed caregiver burden will be collected using the validated The Oberst Caregiving Burden Scale (OCBS), and compared between study groups. Scores range 15-75, with higher scores indicating higher levels of caregiving burden (more time spent or greater difficulty). |
12 months
|
|
Time in therapeutic range in the warfarin sodium group
Tidsram: 12 months
|
Means, as well as rates above 70%, will be compared between study groups. |
12 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Nir Uriel, MD, New York Presbyterian / Columbia University Medical Center
Publikationer och användbara länkar
Allmänna publikationer
- Netuka I, Tucanova Z, Ivak P, Gregor S, Kolesar DM, Marek T, Melenovsky V, Binova J, Dorazilova Z, Hegarova M, Podolec M, Riha H, Connors JM, Mehra MR. A Prospective Randomized Trial of Direct Oral Anticoagulant Therapy With a Fully Magnetically Levitated LVAD: The DOT-HM3 Study. Circulation. 2024 Aug 6;150(6):509-511. doi: 10.1161/CIRCULATIONAHA.124.069726. Epub 2024 Apr 9. No abstract available.
- Shah P, Looby M, Dimond M, Bagchi P, Shah B, Isseh I, Rollins AT, Abdul-Aziz AA, Kennedy J, Tang DG, Klein KM, Casselman S, Vermeulen C, Sheaffer W, Snipes M, Sinha SS, O'Connor CM. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices: The DOAC LVAD Study. JACC Heart Fail. 2024 Sep;12(9):1540-1549. doi: 10.1016/j.jchf.2024.04.013. Epub 2024 May 7.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Cerebrovaskulära störningar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Patologiska processer
- Hjärtsjukdom
- Embolism och trombos
- Patologiska tillstånd, tecken och symtom
- Stroke
- Hjärtsvikt
- Trombos
- Blödning
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Pyraner
- Kumarin
- Bensopyraner
- 4-hydroxikoumariner
- Warfarin
- apixaban
Andra studie-ID-nummer
- AAAV9532
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .